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ABSTRACT
Background. Puumala virus (PUUV) is the most common
species of hantavirus in Central Europe. Nephropathia epide-
mica (NE), caused by PUUV, is characterized by acute kidney
injury (AKI) and thrombocytopenia. The major goals of this
study were to provide a clear clinical phenotyping of AKI in
patients with NE and to develop an easy prediction rule to
identify patients, who are at lower risk to develop severe AKI.
Methods. A cross-sectional prospective survey of 456 adult
patients with serologically conﬁrmed NE was performed. Data
were collected from medical records and prospectively at follow-
up visit. Severe AKI was deﬁned by standard criteria according
to the RIFLE (Risk, Injury, Failure, Loss, End-stage kidney
disease) classiﬁcation. Fuller statistical models were developed
and validated to estimate the probability for severe AKI.
Results. During acute NE, 88% of the patients had AKI ac-
cording to the RILFE criteria during acute NE. A risk index
score for severe AKI was derived by using three independent
risk factors in patients with normal kidney function at time
of diagnosis: thrombocytopenia [two points; odds ratios
(OR): 3.77; 95% conﬁdence intervals (CI): 1.82, 8.03], elevated
C-reactive protein levels (one point; OR: 3.02; 95% CI: 1.42,
6.58) and proteinuria (one point; OR: 3.92; 95% CI: 1.33,
13.35). On the basis of a point score of one or two, the
probability of severe AKI was 0.18 and 0.28 with an area under
the curve of 0.71.
Conclusion. This clinical prediction rule provides a novel and
diagnostically accurate strategy for the potential prevention
and improved management of kidney complications in pa-
tients with NE and, ultimately, for a possible decrease in un-
necessary hospitalization in a high number of patients.
Keywords: acute kidney injury, hanta virus, nephropathia epi-
demica, predictors for severe course, PUUV
INTRODUCTION
Hantavirus disease, along with rotavirus, norovirus, ﬂu and
hepatitis C, is one of the ﬁve most common notiﬁable viral
diseases in Germany [1]. The viruses are single-stranded, en-
veloped RNA viruses of the Bunyaviridae family for which
rodents are the natural reservoir [2] and can lead to haemor-
rhagic fever with renal syndrome (HFRS) in Asia and Europe,
and hantavirus cardiopulmonary syndrome in the Americas
with reported case fatality rates of up to 35% [3–6]. Several
thousand cases of hantavirus infection occur annually
throughout Europe [7]. Although a number of different hanta-
virus species (e.g. Dobrava-Belgrade virus, Tula virus) are cir-
culating in Europe, Puumala virus (PUUV) is by far the most
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frequent cause of disease [1], being responsible for a milder
form of HFRS [8], called nephropathia epidemica (NE).
The clinical picture of NE is characterized by acute kidney
injury (AKI) associated with thrombocytopenia and often pro-
teinuria [9]. A small number of patients with severe AKI are at
risk to develop severe electrolyte disorders, anuria with ﬂuid
overload and uraemia with the requirement for renal replace-
ment therapy or intensive supportive therapy [8], whereas a
high proportion of patients could be treated as outpatients by
a general practitioner or a nephrologist. Previous studies [10–21],
mainly due to the study design’s biases (graduation of the se-
verity of the disease was based on maximum levels of, e.g.
serum creatinine instead of peak levels), were not able to
deﬁne patients at higher or lower risk to develop severe AKI at
time of onset of the disease. Because only a proportion of pa-
tients have to be treated in hospital, risk prediction tools at
time of diagnosis in the management of patients with NE are
warranted.
The aims of this study were to give a clear clinical pheno-
typing in a representative cohort of patients and to establish a
simple prediction score for patients with NE to allow physi-
cians (especially general practitioner or nephrologists) to iden-
tify, at time of onset of disease, patients at low risk for severe
AKI and subsequent complications. The availability of this in-
formation would allow physicians to streamline hospitaliza-
tion in a high proportion of patients.
MATERIALS AND METHODS
Study population
Since 2001, German laboratories have the obligation by law
(Section 7 of the German Law on the Prevention and Control
of Infectious Diseases) to report conﬁrmed cases of HFRS to
the local health authorities. Subsequently, all HFRS cases are
reported to the Robert Koch Institute in Berlin, Germany, the
central federal institution responsible for disease control and
prevention.
A total of 7476 patients with serologically and clinically
conﬁrmed NE were reported to the Robert Koch Institute in
Berlin (Robert Koch Institute, SurvStat, www3.rki.de/SurvStat)
from 2001 to 2012 [21]. In cooperation with four selected local
health authorities in southern Germany (Stuttgart, Boeblingen/
Sindelﬁngen, Esslingen and Reutlingen), we identiﬁed 1570
serologically conﬁrmed patients with NE infected between
2001 and 2012. These patients were contacted by mail and
asked to attend the outpatient clinic between September 2012
and April 2013 for follow-up examination. All patients gave
written consent before participating in the study, which was
approved by the Ethics Committee of the Ethics Commission
of the State Chamber of Medicine in Baden-Wuerttemberg
(Stuttgart) (F-2012-046). Studies were conducted in concord-
ance with the Declaration of Helsinki.
Data acquisition during acute course of NE
Clinical and laboratory data at the time of diagnosis and
during the acute course of the disease were obtained from
medical reports and ﬁles from each patient at the time of
follow-up in our outpatient clinic.
AKI was classiﬁed on the basis of the RIFLE (Risk, Injury,
Failure, Loss, End-stage kidney disease) criteria [22]. Mild/
moderate AKI was deﬁned in patients with no AKI and AKI
Risk (R) and severe AKI was classiﬁed as RIFLE Injury (I) and
RIFLE Failure (F). Oliguria was classiﬁed as temporary loss of
kidney function and refers to a 24-h urine output of <500 mL.
Anuria was classiﬁed as a 24-h urine output of <50 mL.
Leucocytosis was deﬁned as leucocytes >10 × 109/L, and
thrombocytopenia was deﬁned as thrombocytes <90 × 109/L.
Haematuria was deﬁned as a positive dipstick test for erythro-
cytes and over two erythrocytes per high-power ﬁeld.
Proteinuria was deﬁned by an albumin/creatinine ratio (ACR)
>0.25 g/g creatinine in spot urine sample. Abdominal pain
was deﬁned as acute onset of pain in the lower quadrants and
back pain/ﬂank pain was scored positive in patients with acute
onset of pain felt in the low or upper back. Peak or nadir levels
were deﬁned in patients where an increase or a decrease to a
peak level or nadir followed by a decline [serum creatinine
levels, C-reactive protein (CrP) and lactate dehydrogenase
(LDH)] or increment (thrombocytes) was available. Patients
with normal kidney function at the time of diagnosis were
identiﬁed and a risk score for development of severe AKI was
calculated in this patient cohort.
Statistical analysis
Continuous data are expressed as median and IR. Compari-
sons between different groups were made using analysis of
variances (ANOVA) and the Fisher test. Univariate logistic-
regression models were considered with the severity of the
disease as binomial response variables increasing from levels
low to high to ascertain the effect of demographic, clinical and
laboratory variables. We had a quasi-complete separation for
the response variable severity of AKI [RIFLE (0, R versus I, F)]
and an exact logistic regression was performed. To predict
severe AKI, a fuller multivariate logistic-regression model was
constructed by considering factors that were signiﬁcant in the
univariate model (P < 0.05). Finally, to develop a risk score for
clinical practice predicting severe AKI at the time of diagnosis,
we assigned risk factors used in the multivariate analysis and
weighted points proportional to the β regression coefﬁcient
(Supplementary data, Appendix). Odds ratios (OR) are given
with corresponding 95% conﬁdence intervals (CI) and two-
sided P-values. A P-value of <0.05 was considered to be statis-
tically signiﬁcant. Statistical analysis was performed using R
(version 3.0) [23] together with libraries elrm (version 1.2.1)
[24], ROCR (version 1.0) [25], pROC (version 1.5.4), MASS
(version 7.3) [26] and rms (version 4.0) [27]. Validation of the
model was conducted using 5-fold cross-validation [28, 29]
(Supplementary data, Appendix and Figure 3).
RESULTS
Clinical ﬁndings and course of AKI in NE
Between September 2012 and April 2013, 1570 patients
with serologically conﬁrmed NE (laboratory diagnosis was
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conﬁrmed in all patients by detection of circulating anti-
hantavirus IgG- and IgM-antibodies) diagnosed between 2001
and 2012 in Baden-Wuerttemberg were contacted by email.
Overall, 456 patients (29%) were included in the study. This
sample represents 6.1% of ever-reported cases of NE in
Germany. Three patients were excluded by age <18 years at the
time of diagnosis.
The median age at diagnosis was 48 years (IR, 40–59); male
was the predominant gender (290 male and 166 female).
Seventy per cent of patients had AKI according to RIFLE cri-
teria at the time of admission to hospital or to the ambulatory
care physician. During the acute course of the disease, serum
creatinine increased in 31% of these patients, whereas in the
remaining patients a continuous decrease of serum creatinine
could be observed. Overall, 88% of the patients had AKI ac-
cording to the RILFE criteria during acute course of NE.
Serum creatinine peak levels were available in 52% of patients
and duration of onset of symptoms associated with NE to peak
serum creatinine was 8 (7–9) days. At the time of diagnosis,
137 of the 456 patients had normal kidney function. During
acute NE, 61% of patients developed mild/moderate AKI (no
AKI and RIFLE R), whereas 39% of patients developed severe
AKI (RIFLE I and F) based on peak serum creatinine levels.
Eleven patients (3%) required haemodialysis for 4 days (3–4.5)
and three of these four patients had normal kidney function at
time of diagnosis. The following parameters were statistically
signiﬁcant in difference between patients with impaired
kidney function and patients with serum creatinine levels in
the normal range at time of diagnosis: thrombocytes were
lower, percentage of female gender was higher, CrP peak levels
were higher, onset of symptoms to diagnosis was shorter and
AKI (peak creatinine levels and AKI according to RIFLE cri-
teria) was less severe in the normal kidney function group
compared with the patient group presenting with impaired
kidney function at the time of diagnosis of acute NE (Table 1).
During acute course of the disease, 32% of the patients
were treated with antibiotics due to suspected bacterial infec-
tion. The classes of antibiotics used were mainly cephalospor-
ines, different penicillin subgroups and gyrase inhibitors. Dose
adaption based on renal function was done in all patients, and
none of the patients received typical antibiotics with renal
toxicity.
Risk score for predicting AKI in patients with normal
kidney function at time of diagnosis
Patients with normal kidney function at time of diagnosis
were included in the calculation of the risk score. Classiﬁcation
of stage of AKI during acute NE was based on peak serum cre-
atinine levels in these patients. Severe renal involvement was
deﬁned as AKI RIFLE Stage I and F. On univariate analysis,
four variables were statistically signiﬁcant risk factors for
severe AKI and were included in the logistic model (see
Figure 1). A risk index score was derived by using the follow-
ing three independent risk factors associated with severe AKI
at logistic-regression analysis: thrombocytopenia (two points;
OR: 3.77; 95% CI: 1.82, 8.03), 12-fold increase of CrP levels
(one point; OR: 3.02; 95% CI: 1.42, 6.58) and proteinuria (one
point; OR: 3.92; 95% CI: 1.33, 13.35) at time of presentation in
Table 1. Baseline characteristics of study population during acute hantavirus infection
Variable Patients with impaired kidney function
at time of diagnosis
Patients with normal kidney function
at time of diagnosis
n 319 137
Age at diagnosis (years) 48 (40–59) 48 (40–59)
Female/male* 101/218 65/72
Inpatients/outpatients 241/78 94/43
Onset of symptoms prior to admission to hospital (days)** 6 (4–7) 4 (3–6)
Duration of hospital stay (days) 6 (4–9) 7 (5–10)
Laboratory ﬁndings
Thrombocytes (×109/L)** 141 (93–212) 95 (72–135)
Creatinine at admission [mg/dL (0.5–1.4)]** 2.7 (1.8–4.3) 1.0 (0.8–1.2)
Creatinine peak levels [mg/dL (0.5–1.4)]** 4.8 (3.2–6.7) 2.5 (1.6–4.1)
Onset of symptoms to creatinine peak levels (days) 8 (7–9) 8 (7–10)
Renal replacement therapy 8/319 3/137
CrP at admission [mg/dL (0.1–0.4)] 3.9 (2.4–6.4) 4.3 (2.4–8.6)
CrP peak levels [mg/dL (0.1–0.4)]** 4.1 (2.6–6.8) 6.9 (3.7–10.1)
AKI at time of diagnosis**
AKI 319/319 0/137
Risk 102
Injury 71
Failure 146
AKI during course of disease**
AKI 319/319 81/137
Risk 68 27
Injury 62 24
Failure 189 30
CrP, C-reactive protein; RRT, renal replacement therapy; AKI, acute kidney injury.
*P < 0.01.
**P < 0.001.
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the emergency department or in the outpatient clinic. In pa-
tients with no risk factors or only one point using the risk
score, the probability of severe AKI was 0.18 (SEM ± 0.06) and
0.28 (SEM ± 0.07), respectively (see Table 2). Our model
showed satisfactory discrimination with an area under the
curve (AUC) of 0.71 (see Figure 2 and Supplementary data,
Appendix). Internal 5-fold cross-validation of our model re-
vealed an AUC of 0.67 (Figure 3 and Supplementary data, Ap-
pendix). The sensitivity and speciﬁcity of the calculated
probability using the risk score for severe AKI could be
deduced from this ﬁgure by taking into account the calculated
probability for severe AKI, which is mapped on the right Y-
axis in Figure 2. This allows the physician to determine the
sensitivity and speciﬁcity individually after calculating the risk
score (Figure 2).
DISCUSSION
This study comprises, to the best of our knowledge, the largest
cohort of patients with NE reported to date and provides, for
the ﬁrst time, a prediction score to deﬁne patients at low risk
to develop severe kidney disease.
The clinical prediction rule developed in this cross-section-
al study provides a very speciﬁc test that identiﬁes patients
with NE at hospital admission with low risk of development of
Table 2. The risk score allows a calculation of the risk for severe AKI
individually depending on the absence or presence of the described
parameters for each patient at time of diagnosis
Risk factor Points
Thrombocytopenia 2
Elevated CrP levels (12-fold increase) 1
Proteinuria 1
Risk score Probability of severe AKI (%)
0 Point 18
1 Point 28
2 Points 38
3 Points 50
4 Points 64
Total points were calculated by adding together the points for each parameter and the
predicted probability for severe AKI could be determined by using the pocket scoring
system. Normal ranges: CrP (0.1–0.4) mg/dL, thrombocytes (>150) × 109/L.
F IGURE 1 : Univariate logistic-regression analysis for severe AKI (AKI I and AKI F) in study subjects with NE; OR for developing severe AKI
compared with mild/moderate AKI. Severe AKI was deﬁned as RIFLE I and RIFLE F compared with baseline values. The parameter age at time
of diagnosis was deﬁned as age >39 years. 95% CI for the OR. Normal ranges: leucocytes (3.5–10.5) × 109/L. AST, aspartate aminotransferase
(<50) U/L; LDH, lactate dehydrogenase (<250) U/L; CrP, C-reactive protein (0.1–0.4) mg/dL; thrombocytes (>150) × 109/L.
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severe kidney injury. Three variables were identiﬁed, for which
data are easily (even in the outpatient setting) obtained during
assessment of patients, and weighted scores were applied: the
variables were thrombocytopenia, elevated CrP levels and
proteinuria. When a value of one is used for the point score,
the risk to develop severe AKI is 1.8. Given an OR of this mag-
nitude, physicians have to decide whether the patient should
be admitted to hospital or discharged at home with a low risk
for severe AKI. These results suggest that the use of this pre-
diction rule for patients would correctly identify a large pro-
portion of patients with low risk of severe kidney injury. In
clinical practice, stated OR in terms of an event (severe AKI in
our study) are difﬁcult to calculate for physicians and act upon
on a patient-by-patient basis. It is easier to use declared prob-
abilities for the occurrence of a given event. Our model is
coupled with a pocket scoring system, which enables an easy
and rapid calculation of risk for severe AKI at time of diagno-
sis in each patient using only three clinical variables. Due to
the increasing number of patients treated in an ambulatory
setting, we focused on medical history and routine laboratory
workup to develop a simple risk score for the prediction of a
severe AKI in patients with normal kidney function at time of
diagnosis.
In contrast to smaller previously published studies, no
single clinical symptom or sign predicted risk for severe AKI
in our large study population [10, 11, 30–35]. The association
of thrombocytopenia and severe AKI in patients with NE is
widely discussed. Previous smaller studies suggested that
severe thrombocytopenia during acute hantavirus infection is
associated with severity of AKI [9, 20], whereas other studies
found no association. Many of these studies raise methodo-
logical concern regarding grouping of more severe or less
severe AKI, because the maximum measured creatinine value,
not the peak creatinine value, was taken for further calculation
[14, 36, 37].
Regarding laboratory ﬁndings at time of diagnosis, the ele-
vated CrP level (12-fold increase) at time of diagnosis, but not
leucocytosis, was a predictor for severe AKI in our study popu-
lation. Previously, Libraty et al. showed in 36 patients with NE
that leucocyte counts, but not CrP levels during acute NE,
were associated with severe course of the disease [17]. Further-
more, Outinen et al. reported that high plasma IL-6 levels
were associated with severe course of NE and could be used as
a marker of the severity of the disease, whereas high CrP levels
did not indicate severe acute NE [19].
Proteinuria at time of diagnosis was a signiﬁcant predictor
for developing severe AKI. Krautkramer et al. [38] showed
that both tubular and glomerular cells were affected during
hantavirus infection. It is known, too, that damage to tubular,
interstitial and glomerular cells, detected by histologic
changes, is associated with the clinical severity of renal failure
in hantavirus infection [39].
It is noteworthy that this is the ﬁrst study, that has identi-
ﬁed risk factors for development of severe AKI in a large
cohort of patients with no impairment of kidney function at
time of diagnosis. Additionally, severity of AKI was classiﬁed
using creatinine peak levels instead of maximum levels, which
ensures correct graduation of the study population regarding
severity of AKI. Thrombocytes were lower and time of onset of
symptoms to diagnosis was shorter in the normal kidney func-
tion compared with the impaired kidney function group,
which reﬂects earlier stages of the disease. Due to the highly
dynamic process of NE [20], transient thrombocytopenia is
present within the ﬁrst days after the start of symptoms [9].
Within the population of hantavirus patients, age and co-
morbidities of the patients differ widely. In younger patients
F IGURE 3 : ROC curve for the prediction model for severe AKI
with AUC of 0.71 (black line). Internal 5-fold cross-validation of the
model revealed an AUC of 0.67 (red line).
F IGURE 2 : Receiver-operating-characteristic (ROC) curve for the
prediction model for severe AKI with AUC of 0.71. The sensitivity
and speciﬁcity of the calculated probability using the risk score for
severe AKI (Table 2) could be deduced from this ﬁgure by taking into
account the calculated probability for severe AKI, which is mapped
on the right Y-axis. This allows the physician to determine the sensi-
tivity and speciﬁcity individually after calculating the risk score.
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without signiﬁcant comorbidities, the treating physician might
accept a lower sensitivity of the predicted probability of AKI
whereas in older patients higher sensitivity of the predicted
probability is mandatory. Therefore, we did not deﬁne a cutoff
value. From a statistical point of view, it would have been pos-
sible to further increase sensitivity and speciﬁcity including
more variables and/or more not everyday practice parameters.
We decided to keep the model simple and feasible to treat
patients in an outpatient setting and accepted the loss in sensi-
tivity and speciﬁcity. The ﬁnal statistical model showed satis-
factory discrimination with an AUC of 0.71. To ensure that
the model assessment was not conducted on precisely the
same data as used for model development, the AUC of the
ﬁnal model was also examined using predicted probabilities
from 5-fold cross-validation. The AUC values of the proposed
classiﬁer and of one which was based on a 5-fold cross-
validation procedure differed only slightly (0.70 and 0.67).
Our study design has several limitations that have to be ad-
dressed. First, regarding acute course of the disease, we did a
retrospective study of medical case reports, associated with all
known limitations (e.g. time of onset of symptoms associated
with NE to presentation at hospital or to the ambulatory care
physician). Due to a high proportion of patients already pre-
senting with AKI at the time of diagnosis, the number of pa-
tients that could be included in the risk score calculation was
about one-third of the studied patients. Furthermore, more
females were included in the calculation of the risk score com-
pared with the overall study population, but there were no
gender-related differences regarding severity of AKI in our
study population and in the study from Krautkramer et al.
[21]. The risk score could not be used to predict severe AKI
(probability of AKI was 0.64 in patients with four points), but
is a useful tool in everyday clinical practice to minimize the
number of patients who have to be admitted to hospital. Fur-
thermore, our risk score could not be used to predict the diag-
nosis of acute hantavirus infection in, for example, patients
with AKI, abdominal pain and thrombocytopenia. First, dif-
ferential diagnosis, e.g. leptospirosis, sepsis, autoimmune
disease or thrombotic microangiopathy, must be excluded and
laboratory diagnosis of acute hantavirus infection must be
conﬁrmed in all patients by detection of circulating anti-
hantavirus IgG- and IgM-antibodies. Sera from PUUV-in-
fected patients cross-react strongly with Sin Nombre virus and
weakly with Hantaan virus, Seoul virus and Dobrava virus [40,
41]. Although Dobrava-Belgrade virus and Tula virus circulate
in rodent hosts in Germany and might cause an infection in
humans [42–44], almost all hantavirus infections (especially
southern Germany) are caused by PUUV [1, 45]. Recently, in-
testinal biopsies from 13 patients out of this study population
were investigated using immunohistochemistry (IHC). IHC
revealed PUUV nucleocapsid antigen in 11 biopsies from
eight patients during the acute phase of NE [46]. These ﬁnd-
ings minimize the risk of misdiagnosed HFRS caused by other
hantavirus than PUUV in our study.
In summary, NE is responsible for severe AKI in a high
proportion of patients. Thrombocytopenia, elevated CrP levels
and proteinuria at disease onset are likely to be associated with
severe AKI during the acute course of the disease. The clinical
prediction rule developed in this large cross-sectional study
provides a novel and diagnostically accurate strategy for the
potential prevention and improved management of kidney
complications in patients with NE and, ultimately, to prevent
unnecessary hospitalization in a high number of patients.
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